Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
Targets |
Vasopressin V1 receptor
|
---|---|
ln Vitro |
Terlipressin (25 nM; 24-72 hours; IEC-6 cells) treatment dramatically increases the viability, proliferation, and apoptosis of IEC-6 cells[1].
Terlipressin prevents IEC-6 cells from secreting TNF-α and 15-F2t-isoprostane after they are subjected to oxygen and glucose deprivation and then reoxygenated. Through the PI3K signaling pathway, terlipressin administration after OGD reduces OGD/R-induced cell damage[1]. |
ln Vivo |
Terlipressin treatment dramatically reduces IR-induced liver apoptosis, necrosis, and inflammation in a mouse model of nonlethal hepatic ischemia-reperfusion (IR)[3].
|
Cell Assay |
Cell Line: IEC-6 cells induced by oxygen and glucose deprivation/re-oxygenation (OGD/R)
Concentration: 25 nM Incubation Time: 24 hours, 48 hours, 72 hours Result: Significantly increased the proliferation of IEC-6 cells. |
References |
Molecular Formula |
C52H74N16O15S2
|
---|---|
Molecular Weight |
1227.3722
|
Exact Mass |
1227.38
|
Elemental Analysis |
C, 50.89; H, 6.08; N, 18.26; O, 19.55; S, 5.22
|
CAS # |
14636-12-5
|
Related CAS # |
Terlipressin diacetate; 1884420-36-3; Terlipressin acetate; 914453-96-6
|
Appearance |
Solid powder
|
SMILES |
C1C[C@H](N(C1)C(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)NC(=O)CNC(=O)CNC(=O)CN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N
|
InChi Key |
BENFXAYNYRLAIU-QSVFAHTRSA-N
|
InChi Code |
InChI=1S/C52H74N16O15S2/c53-17-5-4-9-31(45(76)60-23-41(57)72)63-51(82)38-10-6-18-68(38)52(83)37-27-85-84-26-36(61-44(75)25-59-43(74)24-58-42(73)22-54)50(81)65-34(20-29-11-13-30(69)14-12-29)48(79)64-33(19-28-7-2-1-3-8-28)47(78)62-32(15-16-39(55)70)46(77)66-35(21-40(56)71)49(80)67-37/h1-3,7-8,11-14,31-38,69H,4-6,9-10,15-27,53-54H2,(H2,55,70)(H2,56,71)(H2,57,72)(H,58,73)(H,59,74)(H,60,76)(H,61,75)(H,62,78)(H,63,82)(H,64,79)(H,65,81)(H,66,77)(H,67,80)/t31-,32-,33-,34-,35-,36-,37-,38-/m0/s1
|
Chemical Name |
(2S)-1-[(4R,7S,10S,13S,16S,19R)-19-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetyl]amino]-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[(2S)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]pyrrolidine-2-carboxamide
|
Synonyms |
Glycylpressin; Remestyp; Terlipressin
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO: ~100 mg/mL (~81.5 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (2.04 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (2.04 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (2.04 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 0.8148 mL | 4.0738 mL | 8.1475 mL | |
5 mM | 0.1630 mL | 0.8148 mL | 1.6295 mL | |
10 mM | 0.0815 mL | 0.4074 mL | 0.8148 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT04460560 | Active Recruiting |
Drug: Terlipressin | Hepatorenal Syndrome | University of Pennsylvania | December 11, 2020 | Phase 3 |
NCT05170230 | Recruiting | Drug: Terlipressin | Myoma | Wael Elbanna Clinic | February 27, 2022 | Not Applicable |
NCT05242783 | Recruiting | Drug: Terlipressin | Myoma | Wael Elbanna Clinic | February 1, 2022 | Not Applicable |
NCT05154279 | Recruiting | Drug: Terlipressin | Laparoscopic Myomectomy | Wael Elbanna Clinic | February 27, 2022 | Not Applicable |
NCT04961528 | Recruiting | Drug: Terlipressin Drug: Placebo Drug: Tranexamic Acid 500 MG |
Hemoptysis | Assistance Publique - Hôpitaux de Paris |
March 27, 2022 | Phase 3 |
Forest plot showing the difference in the control of bleeding in patients treated with terlipressin compared with no vasoactive drugs. Medicine (Baltimore) . 2018 Nov;97(48):e13437. td> |
Forest plot showing the difference in the rebleeding in patients treated with terlipressin compared with balloon tamponade. Medicine (Baltimore) . 2018 Nov;97(48):e13437. td> |
The effect of Terlipressin on the overall mouse hepatic blood perfusion in vivo. Oncotarget . 2016 Oct 25;7(43):69276-69290. td> |
Terlipressin treatment ameliorates hepatic injury and inflammation. Oncotarget . 2016 Oct 25;7(43):69276-69290. td> |
Changes in IEC-6 cell viability following OGD/R. (A) Effect of different concentrations of terlipressin on IEC-6 cell viability following OGD/R. Exp Ther Med . 2017 Jul;14(1):260-266. td> |